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Background-—Transcatheter aortic valve implantation (TAVI) is indicated for patients with aortic stenosis who are intermediate-
high surgical risk. Although all-cause mortality rates after TAVI are established, survival attributable to the procedure is unclear
because of competing causes of mortality. The aim was to report relative survival (RS) after TAVI, which accounts for background
mortality risks in a matched general population.
Methods and Results-—National cohort data (n=6420) from the 2007 to 2014 UK TAVI registry were matched by age, sex,
and year to mortality rates for England and Wales (population, 57.9 million). The Ederer II method related observed patient
survival to that expected from the matched general population. We modelled RS using a ﬂexible parametric approach that
modelled the log cumulative hazard using restricted cubic splines. RS of the TAVI cohort was 95.4%, 90.2%, and 83.8% at
30 days, 1 year, and 3 years, respectively. By 1-year follow-up, mortality hazards in the >85 years age group were not
signiﬁcantly different from those of the matched general population; by 3 years, survival rates were comparable. The ﬂexible
parametric RS model indicated that increasing age was associated with signiﬁcantly lower excess hazards after the
procedure; for example, by 2 years, a 5-year increase in age was associated with 20% lower excess mortality over the
general population.
Conclusions-—RS after TAVI was high, and survival rates in those aged >85 years approximated those of a matched general
population within 3 years. High rates of RS indicate that patients selected for TAVI tolerate the risks of the procedure well. ( J Am
Heart Assoc. 2017;6:e007229. DOI: 10.1161/JAHA.117.007229.)
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A ortic stenosis (AS) is the most common valve patholog-ical feature in Europe and North America and occurs
because of age-related degeneration and calciﬁcation of the
aortic valve. The onset of AS symptoms is associated with
poor prognosis, with an estimated annual mortality rate of
25%.1 Although surgical valve replacement is the mainstay
treatment for AS, randomized controlled trials have demon-
strated the efﬁcacy of transcatheter aortic valve implantation
(TAVI) for symptomatic patients with AS considered to be at
intermediate to high operative risk.2–5 Similarly, studies on
several national TAVI registries have shown favorable short-
and mid-term mortality.6–9 However, because TAVI is recom-
mended in those at high risk, the patients who undergo such a
procedure are older and have more comorbid conditions than
those undergoing alternative treatment options. Conse-
quently, the long-term mortality proﬁle is difﬁcult to assess
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in patients undergoing TAVI because, by virtue of age and
multimorbidity, their risk of dying from other causes is high.
Administrative data on cause of death could be used to
estimate the mortality proﬁle associated with the disease or
treatment in question, but such data are often unreliable.10 An
alternative method is relative survival (RS), which adjusts the
observed mortality for the expected mortality rates within a
matched general population.11,12 Speciﬁcally, overall excess
mortality attributable to the index AS and associated TAVI can
be estimated as the difference between observed and
expected mortality, which forms the RS estimate. Although
RS is commonly used in studies of survival after cancer
diagnosis13 and is beginning to be used in cardiovascular
disease,14,15 to date such methods have not been used to
assess long-term mortality outcomes after TAVI.
The aim of this study was to investigate the survival of
patients treated by TAVI in a national cohort, while adjusting
for underlying expected mortality risks within a matched
general population.
Methods
UK TAVI Registry
Prospective data on all consecutive TAVI procedures in the
United Kingdom are collected in the UK registry through a
Web-based interface provided by the National Institute of
Cardiovascular Outcomes Research; individual TAVI centers
are contacted if there are data inconsistencies. Further details
of the registry have been published previously.16 In summary,
95 variables are recorded, detailing patient demographics,
risk factors for intervention, procedural details, and adverse
outcomes up to the time of hospital discharge. This study
included all consecutive TAVI procedures conducted between
January 1, 2007 and December 31, 2014 across the 32
centers running active TAVI programs in England and Wales.
All-cause mortality was obtained from the Ofﬁce for
National Statistics, providing the life status of English and
Welsh patients. Although mortality information was available
in most cases, we excluded patients with missing life status.
Administrative censoring occurred at the end of follow-up on
May 31, 2015. All survival times were deﬁned as the number
of days between the date of TAVI and either the date of death
or the date of last information on follow-up, up to a maximum
of 3 years after procedure.
Statistical Analysis
RS was deﬁned as the observed survival from the TAVI
registry divided by the expected survival from a matched
general population. RS equal to 1 indicates that the observed
survival is the same as that within the matched general
population, whereas RS <1 means that the observed survival
is worse than that expected within the general population.
This study used the population life tables provided by the
Ofﬁce for National Statistics to derive the population-
expected survival; such life tables are stratiﬁed by age, sex,
year, and country (ie, different tables for England and Wales).
Although the life table mortality estimates will include those
patients undergoing TAVI, the low prevalence of such
procedures undertaken across the general population means
that the bias induced by this will be negligible.11 Furthermore,
although the UK TAVI registry had time-to-event information
censored in 2015, the life tables were only available to 2014.
Hence, the expected population mortality rates for 2015 were
assumed the same as those from 2014. We excluded patients
who were missing data on age, sex, year, or country, which
were used to match to the life tables. All analyses were
conducted in the whole TAVI cohort and across the following
subgroups: age (<80, 80–85, and >85 years), procedure year
(2007–2010 and 2011–2014), and sex.
The Ederer II method was used to estimate RS,11 from
which an estimate of the cumulative excess hazard could be
Clinical Perspective
What Is New?
• Relative survival (RS) adjusts observed mortality, for mor-
tality rates expected within an age-, sex-, year- and region-
matched general population.
• This is the ﬁrst study to apply RS in transcatheter aortic
valve implantation (TAVI), and demonstrates good long-term
RS rates in patients selected for the procedure.
• RS was particularly high in elderly patients, in whom
observed mortality hazards returned to that seen in a
matched general population by 1 year after TAVI.
• High RS within elderly patients with TAVI indicates that a
large proportion of long-term deaths can be accounted for
by the underlying mortality risks within the general
population.
What Are the Clinical Implications?
• Elderly patients with severe aortic stenosis, who are
selected to undergo TAVI, tolerate the risks of the procedure
well, which has important implications from a resource
allocation perspective.
• The careful selection applied to elderly TAVI candidates
appears to control procedure-related mortality rates, mean-
ing that elderly patients should continue to be considered
for TAVI, even with the potential expansion into lower-risk
patients.
• Future reporting of mortality rates from national TAVI
registries should be presented in the context of the patient
population, particularly when comparing rates across coun-
tries where underlying expected mortality may vary consid-
erably.
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Table 1. Baseline and Procedural Characteristics of the UK TAVI Data Set and Across Age Subgroups
Variable
TAVI Cohort
(n=6420)
Aged <80 y
(n=2213)
Aged 80–85 y
(n=1754)
Aged ≥85 y
(n=2453) P Value*
Age, mean (range), y 81.3 (29–101) 73.1 (29–79) 82.2 (80–84) 88.0 (85–101) <0.001
Female sex, n (%) 2972 (46.3) 867 (39.2) 788 (44.9) 1317 (53.7) <0.001
Diabetes mellitus, n (%) <0.001
Nondiabetic 4908 (76.4) 1520 (68.7) 1323 (75.4) 2065 (84.2)
Dietary control 282 (4.39) 105 (4.74) 78 (4.45) 99 (4.04)
Oral medicine 844 (13.1) 379 (17.1) 250 (14.3) 215 (8.76)
Insulin 351 (5.47) 198 (8.95) 91 (5.19) 62 (2.53)
Current or ex-smoker, n (%) 3313 (51.6) 1306 (59.0) 923 (52.6) 1084 (44.2) <0.001
Creatinine, mean (range), lmol/L 114.3 (29.0–1044.0) 118.8 (39–1044) 115.4 (38–681) 109.4 (29–554) <0.001
Renal failure, n (%)† 390 (6.07) 169 (7.64) 118 (6.73) 103 (4.20) <0.001
MI, n (%)
Within 90 d of TAVI 145 (2.26) 51 (2.30) 39 (2.22) 55 (2.24) 0.984
Within 30 d of TAVI 62 (0.97) 24 (1.08) 18 (1.03) 20 (0.82) 0.607
Asthma/COPD, n (%) 1679 (26.2) 744 (33.6) 472 (26.9) 463 (18.9) <0.001
Extracardiac arteriopathy, n (%) 1519 (23.7) 603 (27.2) 422 (24.1) 494 (20.1) <0.001
Calcification of ascending aorta, n (%) 1173 (18.3) 428 (19.3) 345 (19.7) 400 (16.3) 0.005
Atrial fibrillation/flutter, n (%) 1568 (24.4) 482 (21.8) 466 (26.6) 620 (25.3) <0.001
Previous cardiac surgery, n (%) 1999 (31.1) 1009 (45.6) 611 (34.8) 379 (15.5) <0.001
Previous PCI, n (%) 1300 (20.2) 475 (21.5) 371 (21.2) 454 (18.5) 0.020
Weight, mean (range), kg 74.0 (32.0–190.0) 80.1 (32–190) 74.0 (33–141.7) 68.5 (32–163) <0.001
Height, mean (range), m 1.65 (1.10–2.36) 1.67 (1.10–2.01) 1.65 (1.15–1.97) 1.63 (1.16–2.36) <0.001
Critical preoperative state, n (%) 105 (1.64) 50 (2.26) 25 (1.43) 30 (1.22) 0.015
CCS class 4, n (%) 77 (1.20) 30 (1.36) 19 (1.08) 28 (1.14) 0.698
NYHA class ≥III 5140 (80.1) 1776 (80.3) 1413 (80.6) 1951 (79.5) 0.593
LVEF, n (%) <0.001
≥50% 3907 (60.9) 1246 (56.3) 1066 (60.8) 1595 (65.0)
30%–49% 1870 (29.1) 676 (30.5) 502 (28.6) 692 (28.2)
<30% 585 (9.11) 272 (12.3) 165 (9.41) 148 (6.03)
Procedure urgency, n (%) 0.161
Elective 5624 (87.6) 1911 (86.4) 1550 (88.4) 2163 (88.2)
Urgent 749 (11.7) 280 (12.7) 193 (11.0) 276 (11.3)
Emergency/salvage, n (%) 40 (0.62) 19 (0.86) 8 (0.46) 13 (0.53)
Valve type, n (%) 0.248
Edwards SAPIEN 3496 (54.5) 1179 (53.3) 938 (53.5) 1379 (56.2)
Medtronic CoreValve 2680 (41.7) 948 (42.8) 745 (42.5) 987 (40.2)
Other 215 (3.35) 75 (3.39) 64 (3.65) 76 (3.10)
Access route, n (%) <0.001
TF access 4795 (74.7) 1583 (71.5) 1309 (74.6) 1903 (77.6)
TA access 1009 (15.7) 402 (18.2) 279 (15.9) 328 (13.4)
Other access 604 (9.41) 225 (10.2) 161 (9.18) 218 (8.89)
Continued
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obtained. An increasing (decreasing) cumulative excess
hazard through time indicates that the mortality hazard in
the TAVI population was higher (lower) than that expected
from the matched general population. Constant cumulative
excess hazards infer that the observed mortality hazard was
the same as that expected from the general population (ie,
observed hazards of mortality “returned to baseline”); a
cumulative excess hazard of 0 means that observed survival
equals the expected survival (ie, RS=1).
In addition, we calculated expected daily mortality hazards
using the life tables and observed daily mortality hazards
using the Kaplan-Meier estimate. An estimated daily hazard
ratio (HR) was then obtained by dividing the observed and
expected daily hazard rates at each follow-up time within the
ﬁrst year of the procedure. Herein, a daily HR of 1 implies the
observed mortality hazards were the same as those in
the general population, whereas HRs <1 (>1) imply that
mortality hazards after TAVI were lower (higher) than the
general population hazard. A smoother was applied to each of
the daily HRs to estimate a trend through time.17
An alternative estimation of RS was considered that uses a
patient-level approach, which has previously been described
in detail.18 In short, the follow-up time (in days) for each
patient was transformed to give the expected proportion of
the matched general population that would have not survived
that individual’s follow-up. For example, transforming the
observed survival time for a given patient to 0.3 implies that
the individual survived >30% of their matched general
population. A Kaplan-Meier estimate and log-rank test can
then be used directly on the transformed survival times to
compare across strata.
Multivariable modelling of RS was undertaken using a
ﬂexible parametric RS model, which modelled the log cumula-
tive hazard using restricted cubic splines, thereby allowing the
baseline hazard to vary nonlinearly with time.19,20 Covariates in
the model included age (continuous variable), procedure year
(continuous variable), and sex. Other demographic and proce-
dural variableswere not entered into themodel because our aim
was not to identify a causal relationship of age, year, or sex on
RS; rather, the aim was to explore associations of such
variables. Interaction terms between log survival time and age,
year, and sex were included, to estimate time-varying excess
HRs. The degrees of freedom for the baseline and time-varying
coefﬁcients were selected to minimize the Akaike Information
Criterion, with the knots of the splines placed at the centiles of
the uncensored survival times.
R version 3.3.121 was used for all statistical analyses.
Graphical plots were made using the “ggplot2” package,22 the
package “rstpm2” was used to ﬁt the ﬂexible parametric RS
models,23 and the package “relsurv” was used for the Ederer
II RS analysis.24
Results
Between January 1, 2007 and December 31, 2014, 6835
patients received TAVI in either England or Wales; patients with
missing location information (n=337) were removed from the
analysis. Of the remaining 6498 patients, 56 had missing
follow-up time and 22 had missing sex information, leaving
6420 patients (94%) available for analysis. Tables 1 through 3
present baseline characteristics of the whole TAVI cohort and
across age, procedure year and sex subgroups, respectively.
The mean age of patients was 81.3 years, and most patients
were male (53.7%). Older patients generally had fewer baseline
risk factors (Table 1); for instance, the prevalence of renal
failure (P<0.001), asthma/chronic obstructive pulmonary
disease (P<0.001), extracardiac arteriopathy (P<0.001), and
left ventricular ejection fraction <50% (P<0.001) was signiﬁ-
cantly lower for older patients. The median follow-up was
710 days (interquartile range, 351–1219 days), with
14 627 person-years of follow-up.
Relative Survival
In the TAVI cohort, all-cause 30-day, 1-year, and 3-year
observed survival estimates were 94.7%, 83.4%, and 64.5%,
respectively, compared with corresponding RS rates of 95.4%,
90.2%, and 83.8% (Figure 1). Hence, immediately after the
procedure, the hazard of mortality in the TAVI cohort was 50
Table 1. Continued
Variable
TAVI Cohort
(n=6420)
Aged <80 y
(n=2213)
Aged 80–85 y
(n=1754)
Aged ≥85 y
(n=2453) P Value*
Logistic EuroSCORE, mean (range)‡ 21.9 (1.51–93.6) 18.4 (1.51–86.0) 23.2 (5.83–91.1) 24.0 (7.96–93.6) <0.001
STS score, mean (range)‡ 5.06 (0.46–55.4) 3.78 (0.46–44.6) 5.04 (1.15–55.4) 6.22 (1.49–44.8) <0.001
CCS indicates coronary calciﬁcation score; COPD, chronic obstructive pulmonary disease; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NYHA, New York Heart
Association Functional Classiﬁcation; PCI, percutaneous coronary intervention; STS, Society of Thoracic Surgeons; TA, transapical; TAVI, transcatheter aortic valve implantation; and TF,
transfemoral.
*P value indicates the age group comparison.
†Deﬁned as creatinine >200 lmol/L or dialysis for renal failure.
‡The logistic EuroSCORE and the STS score predict the risk of 30-day mortality using a range of risk factors known before the operation.
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Table 2. Baseline Characteristics Across Procedure Year Subgroups
Variable
Procedure Year 2007–2010
(n=1528)
Procedure Year 2011–2014
(n=4892) P Value
Age, mean (range), y 81.5 (44–99) 81.2 (29–101) 0.217
Female sex, n (%) 721 (47.2) 2251 (46.0) 0.440
Diabetes mellitus, n (%) 0.184
Nondiabetic 1188 (77.7) 3720 (76.0)
Dietary control 74 (4.84) 208 (4.25)
Oral medicine 178 (11.6) 666 (13.6)
Insulin 86 (5.63) 265 (5.42)
Current or ex-smoker, n (%) 846 (55.4) 2467 (50.4) 0.021
Creatinine, mean (range), lmol/L 118.5 (37–736) 113.0 (29–1044) 0.004
Renal failure, n (%)* 109 (7.13) 281 (5.74) 0.073
MI, n (%)
Within 90 d of TAVI 39 (2.55) 106 (2.17) 0.452
Within 30 d of TAVI 18 (1.18) 44 (0.90) 0.424
Asthma/COPD, n (%) 421 (27.6) 1258 (25.7) 0.112
Extracardiac arteriopathy, n (%) 418 (27.4) 1101 (22.5) <0.001
Calcification of ascending aorta, n (%) 372 (24.3) 801 (16.4) <0.001
Atrial fibrillation/flutter, n (%) 359 (23.5) 1209 (24.7) 0.338
Previous cardiac surgery, n (%) 483 (31.6) 1516 (31.0) 0.795
Previous PCI, n (%) 332 (21.7) 968 (19.8) 0.136
Weight, mean (range), kg 72.2 (33–153) 74.6 (32–190) <0.001
Height, mean (range), m 1.64 (1.10–1.90) 1.64 (1.14–2.36) 0.054
Critical preoperative state, n (%) 25 (1.64) 80 (1.64) 0.999
CCS class 4, n (%) 26 (1.70) 51 (1.04) 0.057
NYHA class ≥III 1249 (81.7) 3891 (79.5) 0.161
LVEF, n (%) 0.322
≥50% 954 (62.4) 2953 (60.4)
30%–49% 423 (27.7) 1447 (29.6)
<30% 138 (9.03) 447 (9.14)
Procedure urgency, n (%) <0.001
Elective 1385 (90.6) 4239 (86.7)
Urgent 136 (8.90) 613 (12.5)
Emergency/salvage 7 (0.46) 33 (0.67)
Valve type, n (%) <0.001
Edwards SAPIEN 760 (49.7) 2736 (55.9)
Medtronic CoreValve 762 (49.9) 1918 (39.2)
Other 0 (0) 215 (4.39)
Access route, n (%) <0.001
TF access 1029 (67.3) 3766 (77.0)
TA access 389 (25.5) 620 (12.7)
Other access 110 (7.20) 494 (10.1)
CCS indicates coronary calciﬁcation score; COPD, chronic obstructive pulmonary disease; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NYHA, New York Heart
Association Functional Classiﬁcation; PCI, percutaneous coronary intervention; TA, transapical; TAVI, transcatheter aortic valve implantation; and TF, transfemoral.
*Deﬁned as creatinine >200 lmol/L or dialysis for renal failure.
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Table 3. Baseline Characteristics Across Sex Subgroups
Variable Women (n=2972) Men (n=3448) P Value
Age, mean (range), y 82.3 (30–100) 80.4 (29–101) <0.001
Diabetes mellitus, n (%) <0.001
Nondiabetic 2358 (79.3) 2550 (74.0)
Dietary control 119 (4.00) 163 (4.73)
Oral medicine 338 (11.4) 506 (14.7)
Insulin 142 (4.78) 209 (6.06)
Current or ex-smoker, n (%) 1095 (36.8) 2218 (64.3) <0.001
Creatinine, mean (range), lmol/L 100.2 (29–649) 126.4 (39–1044) <0.001
Renal failure, n (%)* 109 (3.67) 281 (8.15) <0.001
MI, n (%)
Within 90 d of TAVI 60 (2.02) 85 (2.47) 0.262
Within 30 d of TAVI 22 (0.74) 40 (1.16) 0.112
Asthma/COPD, n (%) 743 (25.0) 936 (27.1) 0.044
Extracardiac arteriopathy,
n (%)
560 (18.8) 959 (27.8) <0.001
Calcification of ascending
aorta, n (%)
578 (19.4) 595 (17.3) 0.029
Atrial fibrillation/flutter, n (%) 676 (22.7) 892 (25.9) 0.003
Previous cardiac surgery, n (%) 521 (17.5) 1478 (42.9) <0.001
Previous PCI, n (%) 487 (16.4) 813 (23.6) <0.001
Weight, mean (range), kg 67.5 (32–153) 79.6 (38–190) <0.001
Height, mean (range), m 1.57 (1.10–1.94) 1.71 (1.15–2.36) <0.001
Critical preoperative state, n (%) 43 (1.45) 62 (1.80) 0.307
CCS class 4, n (%) 35 (1.18) 42 (1.22) 0.972
NYHA class ≥III 2413 (81.2) 2727 (79.1) 0.041
LVEF, n (%) <0.001
≥50% 2067 (69.5) 1840 (53.4)
30%–49% 731 (24.6) 1139 (33.0)
<30% 147 (4.95) 438 (12.7)
Procedure urgency, n (%) 0.460
Elective 2613 (87.9) 3011 (87.3)
Urgent 340 (11.4) 409 (11.9)
Emergency/salvage 15 (0.50) 25 (0.73)
Valve type, n (%) 0.546
Edwards SAPIEN 1607 (54.1) 1889 (54.8)
Medtronic CoreValve 1244 (41.9) 1436 (41.6)
Other 107 (3.60) 108 (3.13)
Access route, n (%) 0.013
TF access 2270 (76.4) 2525 (73.2)
TA access 430 (14.5) 579 (16.8)
Other access 267 (8.98) 337 (9.77)
CCS indicates coronary calciﬁcation score; COPD, chronic obstructive pulmonary disease; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NYHA, New York Heart
Association Functional Classiﬁcation; PCI, percutaneous coronary intervention; TA, transapical; TAVI, transcatheter aortic valve implantation; and TF, transfemoral.
*Deﬁned as creatinine >200 lmol/L or dialysis for renal failure.
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times higher than that of the matched general population
(Figure 2A). However, the daily HR decreased rapidly, and by
1 year, the observed mortality rate within the TAVI cohort was
only 1.26 times higher than that of the matched general
population (HR, 1.26; 95% conﬁdence interval, 1.05–1.46).
After 1 year, the cumulative excess hazard curve increased at
an approximately constant rate; thus, the TAVI cohort had
marginally higher mortality hazards compared with the general
population up to 3 years after the procedure (Figure 3A).
RS was higher in 2011 to 2014 than for procedures
conducted in 2007 to 2010 (Figure 1). In particular, the
increase in mortality hazard over that in the general population
immediately after the procedure was greater in 2007 to 2010
than in 2011 to 2014, with the daily HRs decaying quicker for
the 2011 to 2014 group (Figure 2B). By 1 year, the daily HR
for both procedural year groups was similar. Consequently,
after 1 year, the cumulative excess hazard curves increased at
a similar rate, meaning that the initial elevation in mortality risk
for earlier procedures relative to the general population
persisted throughout follow-up (Figure 3B).
By 100 days after TAVI, the observed mortality rates within
the >85 years age group were the same as the expected
mortality rateswithin the>85 yearsmatched general population
(HR, 1; Figure 2C). Such a ﬁndingwas not observed in the<80 or
the 80 to 85 years age groups, with the observed mortality
hazard in these groups being higher than that expected from the
matched general populations throughout follow-up (Figure 3C).
In contrast, for the >85 years age group, the cumulative excess
hazard curve plateauedby1 year (because theHRwas1); andby
3 years, the cumulative excess hazard curve had decreased
towards 0 (Figure 3C). Therefore, after surviving the initial high
risk of the procedure, the observed survival rate in the>85 years
age group was approximately similar to that in the >85 years
general population by 3 years (RS1; Figure 1).
Figure 4 shows the survival curves per age group after
transforming each patient’s follow-up time (in days) to
indicate population-expected mortality. For example, when
the expected mortality rate in each representative population
was 20%, the observed cumulative mortality rate was 25% in
the >85 years age group and 36% in the 80 to 85 years age
group. Hence, Figure 4 indicates that, by the end of follow-up,
the mortality rates observed within the >85 years age group
approximated those expected from the general population
(dashed line), with RS signiﬁcantly improved with increasing
age (log-rank test, P<0.001).
Modelling RS
Figure 5 gives the time-dependent excess HRs for age (per 5-
year increase), procedure year (number of years from 2007),
and sex from the ﬂexible parametric RS model. Increasing age
was associated with signiﬁcantly lower excess hazards after
3 months post procedure. For example, at the 2-year follow-
up, the excess HR for age (per 5-year increase) was 0.80 (95%
Figure 1. Kaplan-Meier curves of observed and relative survival (RS). An RS of 1 implies the observed
survival is the same as the expected survival in the matched general population. TAVI indicates
transcatheter aortic valve implantation.
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conﬁdence interval, 0.77–0.84) (Figure 5). Thus, on average, a
given patient was experiencing 20% lower excess mortality
over the general population compared with a similar patient
aged 5 years younger. Moreover, this model highlighted
signiﬁcant temporal improvements in RS for midterm follow-
up, with later procedure years having excess hazards
signiﬁcantly <1, until 2 years after the procedure. The joint
effects of age and procedure year on cumulative excess
hazard are illustrated in Figure 6. RS was similar between
male and female patients throughout follow-up (Figure 5),
supporting the ﬁndings shown in Figure 2D and Figure 3D.
Discussion
This analysis of the UK TAVI registry aimed to compare the
observed survival against that expected from a matched
general population. We found that, although the observed
mortality hazard was high relative to that in the general
population immediately after TAVI, the HR decayed rapidly
within the ﬁrst year of follow-up. After 1 year, RS was
signiﬁcantly higher than all-cause survival, indicating that a
large proportion of the long-term mortality can be accounted
for by the underlying mortality risks within the general
population. By 1 year, most elderly patients were experienc-
ing mortality hazards comparable to the general population
and by 3 years, the excess hazard had reduced sufﬁciently for
the observed survival to return to population-expected
survival rates. Finally, our analysis shows that there were
signiﬁcant improvements in RS for those who underwent TAVI
in 2011 to 2014 compared with 2007 to 2010.
The 1-year all-cause survival rates reported in this study
compare with those from other national registries,7,9,25–27 but
these do not account for competing causes of death. Without
Figure 2. Daily hazard ratios (HRs) for the whole transcatheter aortic valve implantation cohort (A) and
across subgroups of procedure year (B), age groups (C), and sex (D). Estimated daily HRs were calculated as
the observed hazard of mortality divided by the expected hazard from the matched general population. The
lines are the smoother through each of the estimated daily HRs, with 95% conﬁdence intervals shaded.
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cause of death information, the expectedmortality risks derived
from the life tables are a suitable proxy for competing causes of
death, given the low prevalence of TAVI procedures undertaken
across the general population. We found that 1- and 3-year RS
estimates of 90.2% and 83.8%, respectively, were signiﬁcantly
higher than the corresponding all-cause survival rates of 83.4%
and 64.5%. Thus, the initially high excess mortality, induced by
the index AS and associated TAVI, decreased signiﬁcantly
within the ﬁrst year. This supports previous work using cause of
death information, which demonstrated that, although most
short-term mortalities were cardiovascular and procedure
related, beyond 24 months, noncardiovascular causes became
the leading cause of death.25Moreover, the RS rates reported in
this study approximately compare with the cardiovascular
causes of death reported in the high- and intermediate-
risk PARTNER (Placement of Aortic Transcatheter Valves)
randomized trials.3,5 For example, the intermediate-risk
PARTNER trial reported a 1-year cardiovascular death rate of
7.1% and the high-risk trial reported a corresponding rate of
14.3%; these values compare with our reported 1-year RS
mortality rate of 9.8%. Arguably, RS estimates are more useful
to healthcare users and providers than all-cause analyses,
particularly given the decline in cardiovascular causes of
death.26 By examining RS, this analysis suggests that the
mortality risks observed after TAVI return to those expected
within a general population, thereby supporting trial data
showing the effectiveness of the procedure.2,3,5
High rates of RS were particularly evident in most elderly
patients. Older age has previously been a signiﬁcant predictor
of 1-year mortality after multivariable adjustment,9 with
nonagenarians particularly being associated with increased
risk.27 However, by adjusting for mortality risk within the
Figure 3. Cumulative excess hazard curves for the whole transcatheter aortic valve implantation (TAVI)
cohort (A) and across subgroups of procedure year (B), age groups (C), and sex (D). An increasing
(decreasing) cumulative excess hazard indicates worse (better) mortality hazard in the TAVI population
compared with that expected of the general population. A cumulative excess hazard of 0 implies that the
observed survival is the same as the expected survival from the general population.
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underlying population, the present work demonstrates that
elderly patients with TAVI had better survival than younger
patients did, relative to their matched general populations.
Survival in the oldest patients was equivalent to that of a
matched general population by 3 years, which supports the
work of Arsalan et al.27 These researchers demonstrated that,
despite the increased mortality risks of nonagenarians, the
relative difference between the observed rates and an age-
matched general population were less than for those aged
<90 years. Although one needs to consider survival bias, the
current work suggests that a large proportion of long-term
deaths in elderly patients undergoing TAVI are unrelated to
the procedure or the index AS. This has important clinical
implications from a resource use perspective, but further
studies on national registries that exploit administrative cause
of death data are required.
Nevertheless, because TAVI is predominantly undertaken
in patients who are considered high surgical risk, a patient
aged <80 years who undergoes TAVI is likely to have a range
of comorbidities that will inﬂuence subsequent survival.
Hence, the RS estimates for young patients undergoing TAVI
might be biased because we could not adjust for a
correspondingly comorbid young general population. Simi-
larly, after surviving the initial high-risk period after TAVI,
elderly patients are logically more robust than their counter-
parts in the general population. Hence, given octogenarians
survive the initial high risks, it is unsurprising that they
compare with the matched general population. Cardiac teams
will select patients cautiously in the eldest age group, and
this could lead to selection bias. Paradoxically, the older
patients undergoing TAVI had fewer baseline risk factors than
the younger patients did, likely because of careful patient
selection (Table 1). The current analysis suggests that given
such careful selection practices, elderly patients should
continue to be considered for TAVI, given that they appear
to tolerate the risks of the procedure well and their mortality
risks “return to baseline” within 1 year. Recent trial data
highlight a potential expansion of TAVI into intermediate-risk
patients,5 and there is growing interest in identifying cases
where TAVI will be futile.28 In terms of AS-related mortality,
the current study highlights that elderly patients are still
viable and appropriate candidates. Arguably, one should
consider improvements in quality of life and readmissions
when debating if TAVI should be undertaken in the elderly
patients, particularly for cost-effectiveness estimation. Such
data were unavailable in the current analysis. Consequently,
although the mortality risk in elderly patients returned to that
of the matched general population, we were unable to
investigate if there were corresponding improvements in
patient quality of life.
Finally, there have been rapid temporal developments of
TAVI procedure technology and practice. This study found that
Figure 4. Cumulative mortality curves on the transformed time scale per age category. The horizontal
axis represents the mortality rate expected in each representative population, whereas the vertical axis
shows the observed mortality on this transformed time scale. The dashed line represents the null
hypothesis that the matched background mortality rates apply.
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the excess mortality, over that in the general population,
immediately after TAVI was lower for patients who underwent
the procedure between 2011 and 2014. The reasons behind
the faster decrease in excess hazards for the 2011 to 2014
procedure years are unclear from the current work, but likely
reﬂect the changes in patient selection/risk and advances in
procedural techniques/valves. Mortality rates after diagnosis
of AS are decreasing with time,29 with the current work
suggesting similar temporal improvements after TAVI after
accounting for competing causes of death.
Limitations
Several limitations need to be considered when interpreting
the results of this study. One of the main limitations is that
associations cannot be interpreted as casual but rather
highlight those needing explanation. As discussed above, a
limitation of the method is that there is selection bias in
the entire TAVI cohort, which might have led to a false-
negative result in the younger patients. An assessment of
all patients with AS (treated surgically, by TAVI, or
conservatively) might negate such selection bias, but these
data were unavailable; we recommend further work in this
area. Similarly, it is impossible to determine what drives
excess mortality because the RS could not be decomposed
into that from AS, that from TAVI, and that from
comorbidities that are correlated with AS. Indeed, the
Ofﬁce for National Statistics life tables do not stratify by
comorbidities observed in the TAVI registry, which could
inﬂuence the conclusions about the age and year sub-
groups. In addition, the population life tables lag the census
information in the UK TAVI registry, with this analysis
assuming the life tables in 2015 were the same as those in
2014. Although this could lead to bias in the calculation of
expected mortality rates for 2015, the amount of variation
in the life tables between years for any given age, sex, and
country stratum was minimal. Finally, we were only able to
investigate mortality as an end point, without data on
Figure 5. Time-dependent excess hazard ratios (HRs) from the ﬂexible parametric relative survival model. An excess HR of 1 means that the
excess hazard (over that in the general population) was the same between groups.
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quality of life that are increasingly being used to identify
TAVI effectiveness in elderly patients.
Conclusions
In conclusion, this study demonstrates good long-term RS in
patients undergoing TAVI procedures in the United Kingdom.
After surviving the initially high-risk period after TAVI, survival
in elderly patients returned to that expected within the
general population by 3 years.
Acknowledgments
We acknowledge the National Institute for Cardiovascular Outcomes
Research who provided the UK TAVI registry extract for this study.
Sources of Funding
This work was funded by the Medical Research Council
through the Health e-Research Centre, University of
Manchester (MR/K006665/1), and a grant through the North
Staffordshire Heart Committee.
Disclosures
None.
References
1. Carabello BA, Paulus WJ. Aortic stenosis. Lancet. 2009;373:956–966.
2. Leon M, Smith C, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM,
Webb JG, Fontana GP, Makkar RR, Brown DL, Block PC, Guyton RA, Pichard
AD, Bavaria J, Herrmann HC, Douglas PS, Petersen J, Akin JJ, Anderson WN,
Wang D, Pocock S. Transcatheter aortic-valve implantation for aortic stenosis
in patients who cannot undergo surgery. N Engl J Med. 2010;363:1597–1607.
3. Smith C, Leon M, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM,
Webb JG, Fontana GP, Makkar RR, Williams M, Dewey TM, Kapadia S,
Babaliaros V, Thourani VH, Corso P, Pichard AD, Bavaria J, Herrmann HC, Akin
JJ, Anderson WN, Wang D, Pocock S. Transcatheter versus surgical aortic-valve
replacement in high-risk patients. N Engl J Med. 2011;364:2187–2198.
4. Vahanian A, Alﬁeri O, Andreotti F, Antunes MJ, Baron-Esquivias G, Baumgartner
H, Borger MA, Carrel TP, De Bonis M, Evangelista A, Falk V, Iung B, Lancellotti
P, Pierard L, Price S, Schafers H-J, Schuler G, Stepinska J, Swedberg K,
Takkenberg J, Von Oppell UO, Windecker S, Zamorano JL, Zembala M, Bax JJ,
Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C,
Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu
Figure 6. Predicted cumulative excess hazard curves for patients aged 75, 85, and 95 years, across increasing procedure year, obtained from
the ﬂexible parametric relative survival model. The 95% conﬁdence intervals are indicated by the shaded areas.
DOI: 10.1161/JAHA.117.007229 Journal of the American Heart Association 12
Relative Survival After TAVI Martin et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A,
Windecker S, Popescu BA, Von Segesser L, Badano LP, Bunc M, Claeys MJ,
Drinkovic N, Filippatos G, Habib G, Kappetein AP, Kassab R, Lip GYH, Moat N,
Nickenig G, Otto CM, Pepper J, Piazza N, Pieper PG, Rosenhek R, Shuka N,
Schwammenthal E, Schwitter J, Mas PT, Trindade PT, Walther T. Guidelines on
the management of valvular heart disease (version 2012): the Joint Task Force
on the Management of Valvular Heart Disease of the European Society of
Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery
(EACTS). Eur Heart J. 2012;33:2451–2496.
5. Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, Thourani
VH, Tuzcu EM, Miller DC, Herrmann HC, Doshi D, Cohen DJ, Pichard AD,
Kapadia S, Dewey T, Babaliaros V, Szeto WY, Williams MR, Kereiakes D,
Zajarias A, Greason KL, Whisenant BK, Hodson RW, Moses JW, Trento A, Brown
DL, Fearon WF, Pibarot P, Hahn RT, Jaber WA, Anderson WN, Alu MC, Webb JG.
Transcatheter or surgical aortic-valve replacement in intermediate-risk
patients. N Engl J Med. 2016;374:1609–1620.
6. Eltchaninoff H, Prat A, Gilard M, Leguerrier A, Blanchard D, Fournial G, Iung B,
Donzeau-Gouge P, Tribouilloy C, Debrux J-L, Pavie A, Gueret P. Transcatheter
aortic valve implantation: early results of the FRANCE (FRench Aortic National
CoreValve and Edwards) registry. Eur Heart J. 2011;32:191–197.
7. Moat NE, Ludman P, de Belder MA, Bridgewater B, Cunningham AD, Young CP,
Thomas M, Kovac J, Spyt T, MacCarthy PA, Wendler O, Hildick-Smith D, Davies
SW, Trivedi U, Blackman DJ, Levy RD, Brecker SJD, Baumbach A, Daniel T, Gray
H, Mullen MJ. Long-term outcomes after transcatheter aortic valve implanta-
tion in high-risk patients with severe aortic stenosis. J Am Coll Cardiol.
2011;58:2130–2138.
8. Ussia GP, Barbanti M, Petronio AS, Tarantini G, Ettori F, Colombo A, Violini R,
Ramondo A, Santoro G, Klugmann S, Bedogni F, Maisano F, Marzocchi A, Poli
A, De Carlo M, Napodano M, Fiorina C, De Marco F, Antoniucci D, de Cillis E,
Capodanno D, Tamburino C. Transcatheter aortic valve implantation: 3-year
outcomes of self-expanding CoreValve prosthesis. Eur Heart J. 2012;33:969–
976.
9. Ludman PF, Moat N, de Belder MA, Blackman DJ, Duncan A, Banya W,
MacCarthy PA, Cunningham D, Wendler O, Marlee D, Hildick-Smith D, Young
CP, Kovac J, Uren NG, Spyt T, Trivedi U, Howell J, Gray H. Transcatheter aortic
valve implantation in the UK: temporal trends, predictors of outcome and
6 year follow up: a report from the UK TAVI Registry 2007 to 2012.
Circulation. 2015;131:1181–1190.
10. Maudsley G, Williams EMI. “Inaccuracy” in death certiﬁcation: where are we
now? J Public Health Med. 1996;18:59–66.
11. Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical
methodology. Natl Cancer Inst Monogr. 1961;6:101–121.
12. Hall M, Alabas OA, Dondo TB, Jernberg T, Gale CP. Use of relative survival to
evaluate non-ST-elevation myocardial infarction quality of care and clinical
outcomes. Eur Heart J Qual Care Clin Outcomes. 2015;1:85–91.
13. Dickman PW, Sloggett A, Hills M, Hakulinen T. Regression models for relative
survival. Stat Med. 2004;23:51–64.
14. Alabas OA, Brogan RA, Hall M, Almudarra S, Rutherford MJ, Dondo TB,
Feltbower R, Curzen N, de Belder M, Ludman P, Gale CP. Determinants of
excess mortality following unprotected left main stem percutaneous coronary
intervention. Heart. 2016;102:1287–1295. DOI: 10.1136/heartjnl-2015-
308739.
15. Alabas OA, Hall M, Dondo TB, Rutherford MJ, Timmis AD, Batin PD, Deanﬁeld
JE, Hemingway H, Gale CP. Long-term excess mortality associated with
diabetes following acute myocardial infarction: a population-based cohort
study. J Epidemiol Community Health. 2017;71:25–32. jech-2016-207402.
16. Ludman PF. The UK transcatheter aortic valve implantation registry: one of the
suite of registries hosted by the National Institute for Cardiovascular
Outcomes Research (NICOR). Heart. 2012;98:1787–1789.
17. Cleveland WS, Grosse E, Shyu WM. Local regression models. Stat Model S.
1992;2:309–376.
18. Stare J, Henderson R, Pohar M. An individual measure of relative survival. J R
Stat Soc Ser C Appl Stat. 2005;54:115–126.
19. Royston P, Parmar MKB. Flexible parametric proportional-hazards and
proportional-odds models for censored survival data, with application to
prognostic modelling and estimation of treatment effects. Stat Med.
2002;21:2175–2197.
20. Nelson CP, Lambert PC, Squire IB, Jones DR. Flexible parametric models for
relative survival, with application in coronary heart disease. Stat Med.
2007;26:5486–5498.
21. R Core Team R. R: A Language and Environment for Statistical Computing
[Internet]. R Found. Stat. Comput; 2017. http://www.r-project.org/.
Accessed 20/09/2017.
22. Wickham H. ggplot2: Elegant Graphics for Data Analysis. New York, NY:
Springer; 2009.
23. Clements M, Liu X-R. rstpm2: Generalized Survival Models. 2016. R package
version 1.3.2. https://cran.r-project.org/package=rstpm2. Accessed 20/09/
2017.
24. Perme MP. relsurv: Relative Survival. 2016. R package version 2.0-9. https://
cran.r-project.org/package=relsurv. Accessed 20/09/2017.
25. Saia F, Latib A, Ciuca C, Gasparetto V, Napodano M, Sticchi A, Anderlucci L,
Marrozzini C, Naganuma T, Alﬁeri O, Facchin M, Hoxha B, Moretti C, Marzocchi
A, Colombo A, Tarantini G. Causes and timing of death during long-term follow-
up after transcatheter aortic valve replacement. Am Heart J. 2014;168:798–
806.
26. Spoon DB, Psaltis PJ, Singh M, Holmes DR, Gersh BJ, Rihal CS, Lennon RJ,
Moussa ID, Simari RD, Gulati R. Trends in cause of death after percutaneous
coronary intervention. Circulation. 2014;129:1286–1294.
27. Arsalan M, Szerlip M, Vemulapalli S, Holper EM, Arnold SV, Li Z, DiMaio MJ,
Rumsfeld JS, Brown DL, Mack MJ. Should transcatheter aortic valve
replacement be performed in nonagenarians? J Am Coll Cardiol.
2016;67:1387–1395.
28. Puri R, Iung B, Cohen DJ, Rodes-Cabau J. TAVI or no TAVI: identifying patients
unlikely to beneﬁt from transcatheter aortic valve implantation. Eur Heart J.
2016;37:ehv756.
29. Martinsson A, Li X, Andersson C, Nilsson J, Smith JG, Sundquist K. Temporal
trends in the incidence and prognosis of aortic stenosis: a nationwide study of
the Swedish population. Circulation. 2015;131:988–994.
DOI: 10.1161/JAHA.117.007229 Journal of the American Heart Association 13
Relative Survival After TAVI Martin et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
